Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01153035
Other study ID # 104603
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date June 2010
Est. completion date June 2024

Study information

Verified date January 2024
Source University of Arkansas
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study will be to evaluate, in a multi-center setting, the ability of radiofrequency ablation (RFA) of breast cancer lumpectomy sites to extend the "final" negative margin and consequently decrease the rates of re-operation. During the initial breast conservation procedure (lumpectomy), immediately following routine surgical resection of the tumor, radiofrequency energy (RFA) is applied to the wall (bed) of the fresh lumpectomy cavity, thus extending tumor free margin radially beyond the volume of the resected specimen.


Other known NCT identifiers
  • NCT01420380

Recruitment information / eligibility

Status Active, not recruiting
Enrollment 104
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender Female
Age group 50 Years to 100 Years
Eligibility Inclusion Criteria: - Patient is a female, = 50 years of age - The tumor size is = 3 cm (on pre-study radiologic OR clinical exam) - The tumor is unicentric and unilateral - The tumor is not involving the skin - Pathology confirms ductal in situ (DCIS) OR infiltrating ductal carcinoma (IDC), grade I-III - If tumor is IDC, pathology must be hormone receptor positive (ER+ and/or PR+) - Patient signs current written informed consent and HIPAA forms Exclusion Criteria: - Patient is under 50 years of age - Patient is male - Tumor > 3 cm in diameter - Bilateral malignancy - Clinically positive lymph nodes - Tumor involving the skin - Pathology confirms invasive lobular carcinoma - Breast implants - Less than 2 years disease-free survival from previous breast cancer - Neoadjuvant chemotherapy or chemotherapy for another breast cancer within two years

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Radiofrequency Ablation
Breast conservation surgery followed by Radiofrequency Ablation of the cavity

Locations

Country Name City State
United States Comprehensive Breast Care of Denver Denver Colorado
United States University of Arkansas for Medical Sciences Little Rock Arkansas
United States Columbia New York New York
United States Sharp Oncology (Comprehensive Breast Care of San Diego) San Diego California
United States University of Arizona Tucson Arizona
United States The University of Kansas Cancer Center Westwood Kansas

Sponsors (2)

Lead Sponsor Collaborator
University of Arkansas Angiodynamics, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (3)

Klimberg VS, Ochoa D, Henry-Tillman R, Hardee M, Boneti C, Adkins LL, McCarthy M, Tummel E, Lee J, Malak S, Makhoul I, Korourian S. Long-term results of phase II ablation after breast lumpectomy added to extend intraoperative margins (ABLATE l) trial. J Am Coll Surg. 2014 Apr;218(4):741-9. doi: 10.1016/j.jamcollsurg.2013.12.032. Epub 2014 Jan 11. — View Citation

Mackey A, Feldman S, Vaz A, Durrant L, Seaton C, Klimberg VS. Radiofrequency ablation after breast lumpectomy added to extend intraoperative margins in the treatment of breast cancer (ABLATE): a single-institution experience. Ann Surg Oncol. 2012 Aug;19(8 — View Citation

Wilson M, Korourian S, Boneti C, Adkins L, Badgwell B, Lee J, Suzanne Klimberg V. Long-term results of excision followed by radiofrequency ablation as the sole means of local therapy for breast cancer. Ann Surg Oncol. 2012 Oct;19(10):3192-8. doi: 10.1245/ — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Estimate the re-excision rate for close (<3mm) or positive margins How many patients must go back for re-excision of margins Post-surgery (defined as 2 weeks after surgery, to allow time for pathology to be completed)
Primary Decrease local recurrence The patient will be followed closely from the time of surgery through a period of 5 years in order to assess the frequency of local recurrence, defined as a new diagnosis of cancer at or near the site of primary surgery. It is our thought that the addition of RFA to the standard surgical treatment will reduce the number of local recurrences. Monitor throughout 5 year follow-up
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2